TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Consensus Rating of “Moderate Buy” by Brokerages

Posted by on Sep 12th, 2026

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $9.00.

Several research analysts recently issued reports on the company. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, May 31st. Citizens Jmp reiterated a “market outperform” rating and issued a $9.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday, July 17th.

Check Out Our Latest Research Report on HURA

Institutional Trading of TuHURA Biosciences

Several institutional investors have recently added to or reduced their stakes in HURA. Vanguard Group Inc. increased its position in TuHURA Biosciences by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after purchasing an additional 35,426 shares during the period. BlackRock Inc. acquired a new position in shares of TuHURA Biosciences in the 2nd quarter worth approximately $1,615,000. Geode Capital Management LLC lifted its position in shares of TuHURA Biosciences by 6.4% in the 4th quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock worth $501,000 after purchasing an additional 39,710 shares during the period. State Street Corp boosted its stake in shares of TuHURA Biosciences by 4.9% in the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock valued at $219,000 after purchasing an additional 13,594 shares during the last quarter. Finally, Apollon Wealth Management LLC increased its position in shares of TuHURA Biosciences by 17.7% during the first quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock worth $283,000 after buying an additional 23,717 shares during the period. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Price Performance

HURA stock opened at $2.05 on Friday. The company has a market capitalization of $130.65 million, a P/E ratio of -3.80 and a beta of -0.02. The company has a fifty day moving average price of $2.19 and a 200-day moving average price of $2.17. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.18 and a current ratio of 0.18. TuHURA Biosciences has a 52-week low of $0.41 and a 52-week high of $3.43.

TuHURA Biosciences (NASDAQ:HURA – Get Free Report) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, equities analysts expect that TuHURA Biosciences will post -0.55 EPS for the current year.

TuHURA Biosciences Company Profile

(Get Free Report)

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

Featured Articles

Analyst Recommendations for TuHURA Biosciences (NASDAQ:HURA)

Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.